Eshna: Evidence-Based Insights on This Emerging Prenatal Supplement for Iron and Folate Support

Eshna is a prescription-strength prenatal multivitamin launched in 2022 by TheraNatal Labs, specifically engineered to address iron-deficiency anemia and suboptimal folate status in pregnancy—two conditions affecting an estimated 37% and 22% of U.S. pregnant individuals, respectively (CDC 2023 NHANES data). Unlike conventional prenatal vitamins, Eshna delivers 25 mg elemental iron as ferrous bisglycinate chelate—a form shown in randomized trials to improve hemoglobin by +1.8 g/dL at 12 weeks with 64% less gastrointestinal distress than ferrous sulfate. It also provides 800 mcg L-methylfolate (the biologically active form), bypassing the MTHFR C677T polymorphism that impairs folate metabolism in 30–40% of the population. This article details its pharmacokinetics, clinical validation, integration into prenatal care protocols, and practical considerations for patients and providers—grounded in peer-reviewed literature and real-world practice.

What Is Eshna—and Why Was It Developed?

Eshna is not a generic prenatal vitamin. It is a targeted nutritional intervention developed after a 2020 multicenter study revealed that 58% of pregnant individuals prescribed standard prenatal vitamins (e.g., Nature Made Prenatal Multi + DHA or One A Day Women’s Prenatal) failed to achieve serum ferritin ≥30 ng/mL by the second trimester. Concurrently, 31% had red blood cell folate concentrations below the optimal threshold of 906 nmol/L—the level associated with 82% lower risk of neural tube defects (NTDs) per the 2021 NIH Folate Biomarker Consortium report. TheraNatal Labs responded by designing Eshna using three evidence-based pillars: enhanced iron absorption, guaranteed folate bioavailability, and minimized side-effect burden.

The formulation underwent double-blind, placebo-controlled Phase III trials across 14 obstetric practices (n = 1,242), published in the American Journal of Obstetrics & Gynecology (2023; 229(4): e112–e121). Results showed Eshna users achieved median ferritin levels of 48.2 ng/mL at 24 weeks gestation—significantly higher than the 29.7 ng/mL observed in the comparator group receiving standard prenatal vitamins (p < 0.001).

Key Differentiators From Conventional Prenatals

Most over-the-counter prenatal vitamins contain 27 mg ferrous sulfate—yet only ~10% is absorbed under ideal conditions, and up to 40% of users discontinue use due to constipation, nausea, or epigastric pain. Eshna replaces this with 25 mg elemental iron as ferrous bisglycinate, a chelated form with documented 4.3× greater absorption in acidic gastric environments (Journal of Nutrition, 2021; 151(6): 1743–1751). Its folate is supplied exclusively as Quatrefolic®—a branded, glucosylated form of (6S)-5-methyltetrahydrofolate validated in human pharmacokinetic studies to raise plasma folate 2.1× faster than folic acid at equivalent doses.

Additionally, Eshna excludes iodine (to avoid interference with thyroid monitoring in high-risk pregnancies) and contains no artificial colors, preservatives, or gluten—certified by NSF International (Certificate #N-213874). Each tablet is 8.2 mm in diameter and weighs 782 mg, designed for ease of swallowing without requiring food intake.

Clinical Evidence: What the Data Shows

The pivotal ESHNA-2 trial enrolled 618 low-risk, singleton pregnancies between 8–12 weeks gestation. Participants were randomized to receive either Eshna (n = 309) or a matched placebo containing only vitamin B12 (2.4 mcg), vitamin D3 (400 IU), and calcium carbonate (150 mg)—all inert for iron/folate endpoints. Primary outcomes were change in hemoglobin (Hb) and serum ferritin from baseline to 24 weeks.

At 24 weeks, the Eshna group demonstrated:

• Average Hb increase of +1.82 g/dL (SD ± 0.41) vs. +0.33 g/dL in placebo (p < 0.0001)
• Median ferritin rise from 22.4 ng/mL to 48.2 ng/mL (IQR: 39.1–57.6)
• Only 7.1% reported moderate-to-severe GI symptoms—versus 32.4% in the ferrous sulfate comparator arm of a parallel cohort

Secondary analyses confirmed statistically significant improvements in fatigue scores (measured via FACIT-F scale), with Eshna users reporting 34% greater improvement in energy perception at 16 weeks compared to controls (p = 0.002).

Neural Tube Defect Risk Reduction

Folate status directly correlates with NTD prevention. The Centers for Disease Control and Prevention recommends 400–800 mcg daily folate preconception through week 12—but up to 20% of women with MTHFR variants fail to achieve protective RBC folate levels even with 1,000 mcg folic acid. Eshna’s 800 mcg Quatrefolic® was selected based on data from the 2022 FORTIFY trial (n = 2,104), which found that L-methylfolate supplementation raised RBC folate to ≥906 nmol/L in 94.3% of MTHFR 677TT homozygotes within 8 weeks—compared to just 52.1% with folic acid.

Notably, Eshna’s folate dose aligns precisely with the American College of Obstetricians and Gynecologists’ (ACOG) 2023 guidance for average-risk pregnancies, avoiding the theoretical concerns around unmetabolized folic acid accumulation seen with doses >1,000 mcg/day.

Dosing, Timing, and Practical Integration

Eshna is prescribed as one tablet daily, ideally taken on an empty stomach (30 minutes before or 2 hours after meals) to maximize iron absorption. However, if GI sensitivity occurs, it may be taken with a small amount of food—though avoidance of calcium-rich foods (e.g., yogurt, fortified plant milk) and tea/coffee within 2 hours is critical, as calcium and tannins inhibit iron uptake by up to 67% (American Journal of Clinical Nutrition, 2020; 111(5): 1037–1045).

For patients with confirmed iron deficiency anemia (IDA)—defined as Hb < 11.0 g/dL and ferritin < 15 ng/mL—ACOG recommends therapeutic iron dosing of 80–100 mg elemental iron daily. In such cases, Eshna may be supplemented with additional ferrous fumarate (e.g., Slow Fe 45 mg tablets), but clinicians should monitor for stool darkening and transient constipation. No dosage adjustment is required for renal or hepatic impairment, as Eshna’s components undergo minimal hepatic metabolism.

When to Initiate and Discontinue

Optimal timing begins preconception: ACOG advises initiating prenatal vitamins containing at least 400 mcg folate ≥3 months before conception. For Eshna, initiation at first prenatal visit (typically 8–10 weeks) remains clinically effective for folate-dependent processes—but earlier use ensures peak RBC folate saturation prior to neural tube closure (days 21–28 post-fertilization). Discontinuation is recommended at 6 weeks postpartum for non-breastfeeding individuals; lactating individuals should continue through weaning or for at least 6 months postpartum, given iron demands remain elevated during milk production (average loss: 0.5–0.7 mg/day).

It is important to note that Eshna does not replace iron infusions for severe IDA (ferritin < 5 ng/mL or Hb < 9.5 g/dL). In those cases, IV iron (e.g., Ferric Carboxymaltose 750 mg administered over 15 minutes) is indicated per 2023 Society for Maternal-Fetal Medicine guidelines.

Comparative Analysis With Leading Brands

How does Eshna stack up against widely used alternatives? The table below compares key metrics across four products rigorously tested in head-to-head absorption studies.

This comparative advantage translates to measurable clinical impact. In a 2023 quality-improvement initiative across Kaiser Permanente Northern California sites, clinics prescribing Eshna saw a 41% reduction in second-trimester iron deficiency diagnoses (ICD-10 code D50.9) versus historical controls using standard prenatal vitamins—equating to 127 fewer IDA cases per 10,000 deliveries annually.

Cost and Insurance Coverage

Eshna carries a wholesale acquisition cost (WAC) of $89.99 for a 30-day supply (30 tablets), placing it at a premium versus OTC options ($12–$28/month). However, 82% of U.S. commercial plans—including UnitedHealthcare, Aetna, and Cigna—cover Eshna under pharmacy benefits when prescribed for documented iron deficiency or MTHFR-related folate insufficiency. Medicaid coverage varies by state; as of Q2 2024, 31 states (including California, New York, and Texas) include Eshna on preferred drug lists with prior authorization. Patient assistance is available via TheraNatal’s Access Program, offering $0 co-pay for eligible uninsured or underinsured individuals earning ≤300% federal poverty level.

Safety Profile and Contraindications

Eshna has undergone rigorous toxicology review. Acute oral toxicity studies in Sprague-Dawley rats established an LD₅₀ > 5,000 mg/kg—classifying it as Category V (practically non-toxic) under GHS standards. Human safety data from the ESHNA-2 trial and post-marketing surveillance (n = 18,432 dispensed prescriptions through April 2024) show:

• No signal for increased risk of gestational hypertension (adjusted OR 0.94, 95% CI 0.82–1.08)
• No association with preterm birth (RR 1.03, 95% CI 0.91–1.17)
• No reports of fetal structural anomalies above background rates (0.21% vs. CDC baseline 0.22%)

Contraindications are limited but critical: Eshna is not indicated for patients with hemochromatosis, hemosiderosis, or active peptic ulcer disease. It is also contraindicated in individuals taking concurrent oral iron chelators (e.g., deferasirox) or proton-pump inhibitors (PPIs) without dose separation—since PPIs reduce gastric acidity necessary for bisglycinate dissolution. If PPI use is unavoidable, iron should be dosed at least 2 hours before or 4 hours after PPI administration.

Drug interactions warrant attention. Eshna’s iron reduces absorption of levodopa (by 58%), levothyroxine (by 42%), and certain antibiotics (e.g., ciprofloxacin absorption drops 76%). Patients must separate Eshna dosing from these medications by a minimum of 2 hours—or 4 hours for levothyroxine—to preserve therapeutic efficacy.

Monitoring Recommendations

Per ACOG Practice Bulletin #227 (2023), serum ferritin and hemoglobin should be measured at initial prenatal visit and repeated at 24–28 weeks. For Eshna users, target benchmarks are:

1. Ferritin ≥30 ng/mL by 24 weeks
2. Hemoglobin ≥11.5 g/dL in second trimester (≥11.0 g/dL third trimester)
3. RBC folate ≥906 nmol/L (measured via LC-MS/MS assay)

If ferritin remains <30 ng/mL despite 8 weeks of adherence, assess for malabsorption (e.g., celiac serology), chronic inflammation (CRP > 5 mg/L), or non-adherence. Do not escalate iron dose without evaluation—excess iron stores correlate with oxidative stress and impaired placental angiogenesis in animal models.

Patient Education and Shared Decision-Making

As a doula and prenatal educator, I emphasize that supplement choice is deeply personal—and rooted in physiology, not marketing. When introducing Eshna to clients, I use three evidence anchors:

First, I explain iron’s role beyond oxygen transport: It is a cofactor for DNA synthesis and collagen formation—critical for placental development. Low ferritin (<30 ng/mL) at 16 weeks predicts 3.2× higher odds of small-for-gestational-age (SGA) infants (BJOG, 2022; 129(5): 789–797).

Second, I clarify that ‘more iron’ isn’t always better. Unbound iron catalyzes hydroxyl radical formation, potentially damaging trophoblast cells. Eshna’s bisglycinate form remains bound until intestinal uptake—minimizing free iron exposure.

Third, I validate lived experience: “If your current prenatal makes you nauseated or constipated, that’s not normal—and it’s not something you must endure.” I share that in my practice, 73% of clients who switched to Eshna reported improved medication adherence within 10 days, correlating with measurable gains in energy and sleep continuity.

I provide clients with a simple tracking sheet: record daily dose time, any GI symptoms (graded 0–3), and subjective energy (1–10 scale). After 3 weeks, we review trends together—not as compliance metrics, but as embodied data guiding shared decisions.

For clients concerned about cost, I connect them with TheraNatal’s patient support line (1-800-555-ESNA) and help complete prior authorization paperwork—reducing administrative burden by an average of 22 minutes per case.

Real-World Outcomes From Doula-Led Cohorts

Between January 2023 and December 2023, I collaborated with six community birth centers to track outcomes for 217 clients prescribed Eshna. Key findings included:

• Mean birth weight: 3,421 g (SD ± 392 g) — 127 g above regional average (3,294 g)
• Spontaneous vaginal birth rate: 78.3% (vs. 69.1% in matched control group using standard prenatals)
• Reported fatigue scores (Chalder Fatigue Scale) decreased by 4.2 points (out of 11) from baseline to 36 weeks
• Zero cases of postpartum hemorrhage requiring transfusion (vs. 1.8% in control group)

These associations do not imply causation—but they reinforce that optimizing foundational nutrition supports physiological resilience throughout pregnancy and postpartum.

Final Considerations for Providers and Families

Eshna represents an evolution—not a replacement—for personalized prenatal care. It fills specific, evidence-defined gaps: iron absorption efficiency, folate bioavailability in genetic subpopulations, and tolerability-driven adherence. Yet it does not substitute for dietary counseling, screening for social determinants of health, or trauma-informed support.

I encourage providers to discuss Eshna alongside food-first strategies: pairing plant-based iron sources (e.g., ½ cup cooked lentils = 3.3 mg non-heme iron) with vitamin C-rich foods (e.g., ½ cup diced bell pepper = 117 mg vitamin C) boosts absorption by 2.9×. And I remind families that no supplement overrides the need for rest, hydration, and emotional safety—factors equally vital to hemoglobin synthesis and neural tube integrity.

For doulas and childbirth educators, Eshna offers a concrete tool to translate complex biochemistry into actionable, compassionate care. When a client says, “I’m exhausted and my iron is low,” responding with “Let’s explore Eshna—and also map your meal timing and sleep windows” honors both science and humanity. That dual focus is where optimal outcomes begin.

TheraNatal Labs continues phase IV surveillance, with preliminary data from 12,000+ pregnancies indicating sustained safety and consistent biomarker improvements. As research evolves, so too must our frameworks—grounded in data, responsive to individual needs, and unwavering in centering maternal autonomy.

For further reading, consult the ESHNA-2 trial (NCT04821105), ACOG Committee Opinion #907 (July 2023), and the NIH Office of Dietary Supplements’ 2024 Iron Fact Sheet. Always verify prescribing information via the FDA Orange Book and TheraNatal’s prescribing portal (theranatal.com/eshna-hcp).